Harrington K - Search Results

1

Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004).

Nutting CM, Morden JP, Beasley M, Bhide S, Cook A, De Winton E, Emson M, Evans M, Fresco L, Gollins S, Gujral D, Harrington K, Joseph M, Lemon C, Luxon L, van den Blink Q, Mendes R, Miah A, Newbold K, Prestwich R, Robinson M, Sanghera P, Simpson J, Sivaramalingam M, Srihari NN, Sydenham M, Wells E, Witts S, Hall E; COSTAR Investigators. Nutting CM, et al. Among authors: harrington k. Eur J Cancer. 2018 Nov;103:249-258. doi: 10.1016/j.ejca.2018.08.006. Epub 2018 Oct 1. Eur J Cancer. 2018. PMID: 30286418 Free PMC article. Clinical Trial.

2

Manually after-loaded 192Ir low-dose rate brachytherapy after subtotal excision and flap reconstruction of recurrent cervical lymphadenopathy from head and neck cancer.

Nutting C, Horlock N, A'Hern R, Searle A, Henk JM, Rhys-Evans P, Harrington K. Nutting C, et al. Among authors: harrington k. Radiother Oncol. 2006 Jul;80(1):39-42. doi: 10.1016/j.radonc.2006.06.012. Epub 2006 Jul 25. Radiother Oncol. 2006. PMID: 16870288

3

Intensity modulated radiotherapy improves target coverage and parotid gland sparing when delivering total mucosal irradiation in patients with squamous cell carcinoma of head and neck of unknown primary site.

Bhide S, Clark C, Harrington K, Nutting CM. Bhide S, et al. Among authors: harrington k. Med Dosim. 2007 Fall;32(3):188-95. doi: 10.1016/j.meddos.2007.01.002. Med Dosim. 2007. PMID: 17707198

4

Prospective, longitudinal electroglottographic study of voice recovery following accelerated hypofractionated radiotherapy for T1/T2 larynx cancer.

Kazi R, Venkitaraman R, Johnson C, Prasad V, Clarke P, Newbold K, Rhys-Evans P, Nutting C, Harrington K. Kazi R, et al. Among authors: harrington k. Radiother Oncol. 2008 May;87(2):230-6. doi: 10.1016/j.radonc.2008.01.006. Epub 2008 Jan 30. Radiother Oncol. 2008. PMID: 18237804

5

An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer.

Newbold K, Castellano I, Charles-Edwards E, Mears D, Sohaib A, Leach M, Rhys-Evans P, Clarke P, Fisher C, Harrington K, Nutting C. Newbold K, et al. Among authors: harrington k. Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):29-37. doi: 10.1016/j.ijrobp.2008.07.039. Epub 2008 Nov 25. Int J Radiat Oncol Biol Phys. 2009. PMID: 19036529

6

Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis.

Dandekar P, Harmer C, Barbachano Y, Rhys-Evans P, Harrington K, Nutting C, Newbold K. Dandekar P, et al. Among authors: harrington k. Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):518-21. doi: 10.1016/j.ijrobp.2008.08.016. Epub 2009 Apr 22. Int J Radiat Oncol Biol Phys. 2009. PMID: 19395202

7

Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.

Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C. Hoskin PJ, et al. Among authors: harrington k. J Clin Oncol. 2009 Dec 1;27(34):5751-6. doi: 10.1200/JCO.2009.22.3693. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884550 Clinical Trial.

8

Familial nonmedullary thyroid cancer: a review of the genetics.

Khan A, Smellie J, Nutting C, Harrington K, Newbold K. Khan A, et al. Among authors: harrington k. Thyroid. 2010 Jul;20(7):795-801. doi: 10.1089/thy.2009.0216. Thyroid. 2010. PMID: 20465534 Review.

9

Evidence-based review: quality of life following head and neck intensity-modulated radiotherapy.

Scott-Brown M, Miah A, Harrington K, Nutting C. Scott-Brown M, et al. Among authors: harrington k. Radiother Oncol. 2010 Nov;97(2):249-57. doi: 10.1016/j.radonc.2010.08.004. Radiother Oncol. 2010. PMID: 20817284 Review.

10

Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.

Steele L, Errington F, Prestwich R, Ilett E, Harrington K, Pandha H, Coffey M, Selby P, Vile R, Melcher A. Steele L, et al. Among authors: harrington k. Mol Cancer. 2011 Feb 21;10:20. doi: 10.1186/1476-4598-10-20. Mol Cancer. 2011. PMID: 21338484 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,359 results

Search Page

Filters